https://curativeventures.com/2018/06/20/iteos-therapeutics-completes-75-million-series-b-financing/ 2018-06-20T15:17:50+00:00 https://curativeventures.com/2014/02/17/costim-pharmaceuticals-inc-acquired-by-novartis/ 2019-03-07T05:43:28+00:00 https://curativeventures.com/2019/02/13/tcr2-therapeutics-prices-ipo-of-5-mln-shares-at-15-00-shr/ 2019-03-07T17:12:58+00:00 https://curativeventures.com/2018/03/21/tcr2-therapeutics-raises-125-million-in-oversubscribed-series-b-financing/ 2019-03-07T17:13:14+00:00 https://curativeventures.com/2019/02/14/peloton-therapeutics-secures-150-million-in-series-e-financing/ 2019-08-09T16:25:48+00:00 https://curativeventures.com/2019/05/12/merck-to-acquire-peloton-therapeutics-bolstering-oncology-pipeline/ 2019-08-09T16:37:18+00:00 https://curativeventures.com/2019/08/26/vertex-enters-duchenne-therapy-market-with-1b-acquisition-of-exonics/ 2019-08-26T15:12:52+00:00 https://curativeventures.com/2021/03/23/instil-bio-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2021-04-08T02:45:36+00:00 https://curativeventures.com/2024/08/01/instil-bio-and-immuneonco-announce-license-and-collaboration-agreement-for-development-of-imm2510-a-potentially-best-in-class-pd-l1xvegf-bispecific-antibody-and-imm27m-a-novel-next-generation-anti/ 2025-01-07T19:06:02+00:00